Arch Therapeutics, Inc. (ARTH) Starts Presentation at 29th Annual ROTH Conference
Arch Therapeutics (OTCQB: ARTH) is a biotech company developing an innovative, elegant and superior approach to the rapid cessation of bleeding (hemostasis) and control of fluid leakage (sealant) during surgery and trauma care. The underlying technology, exclusively licensed from a leading university, supports an innovative platform of smart materials that fulfill the criteria as a solution for a specialized field we call, “stasis and barrier applications.” For more information, visit the company’s website at www.archtherapeutics.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news…